SLDB — Solid Biosciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1707502 ·
Last close
$8.06
Market Cap
$793.50M
52W High
$11.45
52W Low
$6.00
ADV30
2,148,074
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -57,308,000 | -56,737,000 | 422,893,000 | 297,099,000 | 48,761,000 |
| Dec 2025 | 0 | — | -49,403,000 | -49,787,000 | 232,540,000 | 59,900,000 | 52,530,000 |
| Sep 2025 | 0 | — | -48,058,000 | -45,776,000 | 273,914,000 | 61,364,000 | 55,966,000 |
| Jun 2025 | 0 | — | -41,693,000 | -39,480,000 | 308,292,000 | 138,933,000 | 50,001,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-171,669,000
Investing CF
$13,767,000
Financing CF
$243,745,000
CapEx
$-1,192,000
Dividends Paid
—
Buybacks
$-14,551,000
EPS Diluted TTM
$-2.01
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,014,512,000
Inventory
—
Receivables
—
ST Investments
$83,581,000
EBIT TTM
$-193,618,000
Pretax Income TTM
$-191,780,000
Interest Exp TTM
$203,000
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -179,206,000 | -174,325,000 | 232,540,000 | 52,530,000 | — | -156,289,000 |
| Dec 2024 | 0 | -129,728,000 | -124,697,000 | 188,662,000 | 51,416,000 | — | -100,012,000 |
| Dec 2023 | 0 | -104,315,000 | -96,015,000 | 164,939,000 | 38,458,000 | — | -94,180,000 |
| Dec 2022 | 8,094,000 | -99,274,000 | -85,981,000 | 260,252,000 | 48,586,000 | — | -97,977,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.96
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DBVT | DBV Technologies S.A. | $799.04M | $13.50 | — |
| CADL | Candel Therapeutics, Inc. | $733.44M | $10.01 | — |
| AURA | Aura Biosciences, Inc. | $725.09M | $7.01 | — |
| SANA | Sana Biotechnology, Inc. | $871.05M | $3.13 | — |
| ODTX | Odyssey Therapeutics, Inc. | $909.23M | $18.93 | — |
News headlines (Yahoo Finance, 1h cache)
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?
2026-07-02 03:28 · Yahoo
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
2026-06-18 15:04 · Yahoo
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
2026-06-08 07:00 · Yahoo
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
2026-06-02 11:00 · Yahoo
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 20:05 · Yahoo
Solid Biosciences to Participate at Upcoming Investor Conferences
2026-06-01 12:00 · Yahoo
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?
2026-05-20 12:36 · Yahoo
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 20:08 · Yahoo
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
2026-05-07 12:00 · Yahoo
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
2026-04-30 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.